On 30 November 2017, the journal MDPI
published an article entitled “Novel Artificial Tears Containing Cross-Linked Hyaluronic Acid: An In Vitro Re-Epithelialization Study “
written by Arianna Fallacara (1), Silvia Vertuani (1),, Giacomo Panozzo (2), Alessandra Pecorelli (3), Giuseppe Valacchi (3) and Stefano Manfredini (1). Thanks to the important collaboration with the authors of the publication, COC Farmaceutici has launched Hyalucross
, a new eye drop based on the cross-linked hyaluronic acid object of the article.
Hyalucross is a sterile solution for ophthalmic use manufactured by COC Farmaceutici that contains the cross-linked hyaluronic acid object of the research. Cross-linked hyaluronic acid gives a high level of hydration and persistence on the eye surface
, able to promote a higher tear film stability and protects the corneal surface. The product is used for its lubricating, prolonged moisturizing and reparative actions able to give relief to dry, sore or tired eyes and also as an adjuvant in case of inflammatory reactions. Suitable for everyday use and evening.
Hyalucross is CE marked and can be directly marketed all through EU countries and also overseas subject to local registration
, in single dose and multi-dose plastic containers, including ophthalmic preservative-free bottles. Read the full article
The photo shows an example of possible customization.
(1) Department of Life Sciences and Biotechnology, Master Course in Cosmetic Science and Technology (COSMAST), University of Ferrara, Via L. Borsari 46, 44121 Ferrara, Italy
(2) Ophthalmology Unit, Azienda ULSS n.22, 37012 Bussolengo, Italy
(3) Department of Animal Sciences, Plants for Human Health Institute, North Carolina State University, NC Research Campus, 600 Laureate Way, Kannapolis, NC 28081, USA